21st Annual NATA Symposium

21st Annual NATA Symposium, Athens 2020The 21st Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place on April 23-24, 2020 in Athens, Greece.

Please click on the link below for more information
21st Annual Symposium General Information

Follow NATA on LinkedIn and Twitter

Join NATA's group on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

News from the Industry

New clinical data support efficacy of fibrinogen concentrate (fibryga®) in treating acquired fibrinogen deficiency and lead to label extension in Europe

Fibrinogen replacement is widely accepted as an approach to managing acquired fibrinogen deficiency (AFD) in patients with critical bleeding, despite a lack of evidence until now from controlled clinical studies. Data from two comparative studies with Octapharma's highly-purified, dual pathogen-inactivated fibrinogen concentrate fibryga® have recently been published, and provide robust clinical support for this treatment approach.

The outcomes of a randomised, controlled clinical trial investigating approaches to bleeding control during cytoreductive surgery in 55 patients with pseudomyxoma peritonei were presented at the ISTH 2019 Congress in July. Fibrinogen replacement was effective for treatment of AFD in all cases, as measured by overall haemostatic efficacy. The results demonstrated non-inferiority of fibryga® (n = 22) compared with cryoprecipitate (n = 23) (p < 0.0095 for non-inferiority).

More recently, data from the first large multicentre, randomised controlled trial in AFD were published (JAMA, 2019). In a study of 827 patients undergoing cardiac surgery, fibryga® met the non-inferiority endpoint compared with cryoprecipitate (p < 0.001 for non-inferiority). Safety profiles of fibryga® and cryoprecipitate were comparable. Based on these clinical data, fibryga® received approval in the European Union for treatment of acquired fibrinogen deficiencies.

Read more at www.fibrinogendeficiency.com.

News

Patient Blood Management is not about blood transfusion: it is about patients' outcomes

In an editorial published in Blood Transfusion, Thomas Frietsch, Aryeh Shander, David Faraoni and Jean-Francois Hardy comment on the results of the Frankfurt Consensus Conference on Patient Blood Management (Müller MM et al. JAMA 2019;321:983-97).

"We can only agree with some of the recommendations put forward by the 2018 Frankfurt Consensus Conference, the authors write, but we feel that a true consensus between blood bankers, clinicians well-versed in the management of patients undergoing major surgery at risk of bleeding and researchers in the field would have sent a stronger and more relevant message in favour of PBM."

"PBM is not an offensive against producers of blood components. PBM aims to improve the outcomes of patients at risk through the optimisation of the patient's condition before, during and after the procedure."

Read more on this

Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement

Postpartum haemorrhage remains a common obstetric emergency and is the leading cause for maternal mortality worldwide.

The aim of this multidisciplinary consensus statement, published online ahead of print in Blood Transfusion on February 6, 2019, is to provide recommendations on the prevention and treatment of postpartum haemorrhage as part of patient blood management in obstetrics.

It was developed by NATA in collaboration with the International Federation of Gynaecology and Obstetrics (FIGO), the European Board and College of Obstetrics and Gynaecology (EBCOG) and the European Society of Anaesthesiology (ESA).

Read more on this

From the Literature

Dec 16, 2019

Published: Dec 2019

Kaserer A, Rössler J, Braun J, et al.

Impact of a Patient Blood Management monitoring and feedback programme on allogeneic blood transfusions and related costs.
Anaesthesia 2019;74:1534-1541.

#

NATA REVIEW:
While Patient Blood Management (PBM) is becoming a new standard worldwide with evidence-based and expert consensus...
REVIEW by:
S. M. Goobie

Published: Nov 2019

Bah A, Muhammad AK, Wegmuller R, et al.

Hepcidin-guided screen-and-treat interventions against iron-deficiency anaemia in pregnancy: a randomised controlled trial in The Gambia.
Lancet Glob Health 2019;7:e1564-e1574.

#

NATA REVIEW:
The World Health Organization recommends that pregnant women should take supplements containing 30-60 mg...
REVIEW by:
M. Muñoz

Published: Nov 2019

CRASH-3 trial collaborators

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
Lancet 2019;394:1713-1723.

#

NATA REVIEW:
Tranexamic acid administered within 3 hours of injury in patients with head trauma reduces death. I...
REVIEW by:
B. H. Hunt

Published: Nov 2019

Harenberg J, Beyer-Westendorf J, Crowther M, et al.

Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine – a multicenter trial.
Thromb Haemost 2019; Nov 8 [Epub ahead of print].

#

NATA REVIEW:
Harenberg et al. have developped a rapid colorimetric point-of-care test using patient urine sample...
REVIEW by:
C.-M. Samama

Published: Nov 2019

Ming Y, Liu J, Zhang F, et al.

Transfusion of red blood cells, fresh frozen plasma, or platelets is associated with mortality and infection after cardiac surgery in a dose-dependent manner.
Anesth Analg 2019; Nov 5 [Epub ahead of print].

#

NATA REVIEW:
The authors sought to determine whether transfusion of platelets or fresh frozen plasma, in addition to RBCs,...
REVIEW by:
J. M. Cholette

Published: Nov 2019

Raphael J, Mazer CD, Subramani S, et al.

Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients.
J Cardiothorac Vasc Anesth 2019;33:2887-2899.

#

NATA REVIEW:
Bleeding after cardiac surgery is a common and serious complication leading to transfusion of multiple blood...
REVIEW by:
J. M. Cholette